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Abstract
Targeted inhibitors elicit heterogeneous clinical responses in genetically stratified groups of 
patients. While most studies focus on tumor intrinsic properties, factors in the tumor 
microenvironment were recently found to modulate the response to inhibitors. Here, we show that 
in cutaneous BRAF V600E melanoma, the cytokine TNFα blocks RAF-inhibitor-induced 
apoptosis via activation of nuclear factor κB (NFκB). Several NFκB-dependent factors are up-
regulated following TNFα and RAF inhibitor treatment. Of these factors, we show that death 
receptor inhibitor cellular caspase 8 (FLICE)-like inhibitory protein (c-FLIP) is required for 
TNFα-induced protection against RAF inhibitor. Overexpression of c-FLIP_S or c-FLIP_L 
isoform decreased RAF inhibitor-induced apoptosis in the absence of TNFα. Importantly, 
targeting NFκB enhances response to RAF inhibitor in vitro and in vivo. Together, our results 
show mechanistic evidence for cytokine-mediated resistance to RAF inhibitor and provide a 
preclinical rationale for the strategy of co-targeting the RAF-MEK-ERK1/2 pathway and the 
TNFα/NFκB axis to treat mutant BRAF melanomas.
INTRODUCTION
Targeted inhibitors, such as vemurafenib and dabrafenib, elicit strong but heterogeneous 
effects in mutant BRAF V600E cutaneous melanoma patients (Flaherty et al., 2010; 
Hauschild et al., 2012; Long et al., 2012; Sosman et al., 2012). However, approximately 
50% of patients do not achieve a partial or complete response. Furthermore, many patients 
that achieve an objective response ultimately develop acquired resistance (Hartsough et al., 
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2014). Heterogeneous modes of resistance have been identified in patient samples with 
reactivation of extracellular signal-regulated kinase 1/2 (ERK1/2) signaling being a frequent 
mechanism. Simultaneously targeting multiple steps in the RAF-MEK-ERK1/2 pathway is 
more efficacious than single agent therapy (Flaherty et al., 2012); however, resistant tumors 
still emerge. These findings indicate that the efficacy of single pathway targeting is limited 
and strategies need to be developed to co-target alternative pathways.
The tumor microenvironment modulates the response to targeted therapies. Growth factors 
including hepatocyte growth factor and neuregulin 1 provide protective signals 
counteracting the effects of vemurafenib (Abel et al., 2013; Straussman et al., 2012; Wilson 
et al., 2012). Accordingly, co-targeting the corresponding receptor tyrosine kinase (RTK) 
pathway and RAF-MEK-ERK pathway elicited better outcome than single pathway 
targeting (Abel et al., 2013; Lito et al., 2012; Straussman et al., 2012; Wilson et al., 2012). 
However, due to the complex composition of tumor microenvironment, additional 
compensatory pathways will likely modulate the response to RAF inhibitors and will need to 
be targeted to maximize the effects of RAF and MEK inhibitors in melanoma.
Advanced stage melanoma cells often have constitutive IκB kinase (IKK) and nuclear factor 
κB (NFκB) activity (Meyskens et al., 1999; Yang and Richmond, 2001). NFκB is a family 
of protein complexes that controls the transcription of genes involved in inflammatory 
response and cell survival (Karin and Lin, 2002; Lawrence, 2009). Anti-apoptotic targets of 
NFκB include Bcl-2 (Catz and Johnson, 2001) and Bcl-xl (Chen et al., 2000)), the inhibitor 
of apoptosis family proteins (c-IAP1 (Stehlik et al., 1998a), c-IAP2 (Stehlik et al., 1998a), 
XIAP (Stehlik et al., 1998b), survivin (Kawakami et al., 2005)) and death receptor inhibitor 
cellular caspase-8 (FLICE)-like inhibitory protein (c-FLIP) (Kreuz et al., 2001) and, 
therefore, NFκB is implicated in radiation- and chemo-resistance in many cancers (Magne et 
al., 2006; Wang et al., 1999).
In tumor microenvironment, tumor-associated macrophages (TAM) produce cytokines such 
as TNFα and IL-1β, which are potent inducers of NFκB pathway. Studies have shown that 
TAM infiltration is associated with melanoma stage and angiogenesis (Torisu et al., 2000) 
and may serve as prognostic marker for AJCC stage I/II melanoma (Jensen et al., 2009). 
Furthermore, targeting the tumor NFκB pathway or blocking TNFα signaling in TAMs 
sensitized melanoma cells to chemo- or radiation-therapies (Amiri et al., 2004; Meng et al., 
2010). TNFα also blocks apoptosis induced by MEK inhibitor or BRAF depletion in mutant 
BRAF melanoma cells, although the underlying mechanism remains unclear (Gray-Schopfer 
et al., 2007). Here, we tested the role of NFκB pathway in the responses of mutant BRAF 
melanoma cells to RAF inhibition. We show that activation of NFκB pathway by TNFα 
protects melanoma cells against the RAF inhibitor via up-regulation of the anti-apoptotic 
protein c-FLIP. Importantly, targeting the NFκB pathway sensitized melanoma cells to the 
RAF inhibitor in vitro and in vivo. Our data provide the rationale for co-targeting the RAF-
MEK-ERK and NFκB pathways to treat mutant BRAF melanoma.
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RESULTS
The NFκB agonist, TNFα, protects melanoma cells from RAF-inhibitor induced apoptosis
To test the role of the NFκB pathway in the response melanoma cells to RAF inhibitor, we 
treated three mutant BRAF melanoma cells with TNFα, and examined their response to 
PLX4720, the tool compound for vemurafenib (Tsai et al., 2008). Treatment with TNFα 
significantly enhanced NFκB reporter activity in both untreated and RAF inhibitor-treated 
cells, although activation was slightly lower in the presence of PLX4720 (Fig. 1a). 
Consistent with previous observations (Shao and Aplin, 2010), PLX4720 elicited strong 
cytotoxic effects in BRAF V600E melanoma cells (Fig. 1b-c, Fig. S1). TNFα treatment 
alone slightly increased the basal level of cell death in A375 but not M238 and M229 cells. 
Importantly, TNFα strongly protected multiple BRAF V600E melanoma cells against the 
cytotoxic effect of PLX4720 but had little impact on cell cycle progression (Fig. 1b-c, Fig. 
S1). TNFα was also protective against the RAF plus MEK inhibitor combination but did not 
reduce death induced by etoposide (Fig. S1c). Cleaved caspase 3 was detected 24-48 hours 
following PLX4720 treatment and strongly inhibited by TNFα stimulation (Fig. 1c). 
Furthermore, activation of both intrinsic (caspase 9) and extrinsic (caspase 8) apoptosis 
pathways was detected following PLX4720 treatment and was inhibited by TNFα (Fig. 1c). 
Cleavage of caspase 3 and 9 was first detected at ~18 hours following PLX4720 treatment 
while caspase 8 cleavage showed a delay of 2-4 hours (Fig. S2a), suggesting caspase 9 
activation is an upstream event in RAF inhibitor-induced apoptosis. Interestingly, caspase 8 
depletion reduced cleavage of caspase 3 and 9 (Fig. S2b), suggesting crosstalk between 
these caspases. Together, these results show that TNFα protects melanoma cells from RAF-
inhibitor induced apoptosis and counteracts the activation of caspase 3, 8 and 9.
NFκB signaling is required for TNFα-mediated protection from RAF inhibitor-induced 
apoptosis
Next, we tested the requirement for NFκB in TNFα-mediated protection. We selectively 
depleted the NFκB components, p50 and p65, alone and in combination, as confirmed by 
Western blot (Fig. 2a). Depletion of p50 and p65 individually or in combination completely 
reversed the TNFα-mediated protection against the RAF inhibitor cytotoxicity (Fig. 2b-d). 
Knockdown of NFκB components also sensitized melanoma cells to TNFα treatment, 
indicating that NFκB may confer natural resistance of melanoma cells to TNFα-induced 
apoptosis. In the case of A375 cells, TNFα treatment in p65 and p65 plus p50 knockdowns 
further augmented the apoptotic effect of PLX4720 (Fig. 2b). These data indicate that 
TNFα-mediated protection against RAF inhibitor requires NFκB. By contrast, NFκB p65 
and p50 knockdowns had little impact on the sensitivity of melanoma cells to non-targeted 
chemotherapeutics such as etoposide and cisplatin (Fig. S3a and 3b).
c-IAP2 and c-FLIP are up-regulated upon TNFα and PLX4720 treatment in an NFκB-
dependent manner
To identify the downstream effectors of NFκB that may account for the protection against 
PLX4720, we analyzed the expression of NFκB target proteins known to regulate apoptosis. 
We focused on differences in target expression in cells treated with PLX4720 alone and with 
a combination of PLX4720 and TNFα. Up-regulation of the BH3-only proteins, Bim-EL 
Shao et al. Page 3
J Invest Dermatol. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and Bmf, and down-regulation of the Bcl-2 family protein, Mcl-1, by PLX4720 (Boisvert-
Adamo et al., 2009; Shao and Aplin, 2010) were not significantly altered by TNFα (Fig. 
S4a). Furthermore, no apparent TNFα-regulated differences were observed in other Bcl-2 
family proteins and most IAP family proteins (XIAP, survivin, livin and c-IAP1) (Fig. S4a). 
By contrast, two anti-apoptotic proteins, c-IAP2 and c-FLIP, were up-regulated by TNFα 
and PLX4720 when compared to PLX4720 alone (Fig. 3a)
c-IAP2 was up-regulated by TNFα alone in A375 and M238 cells and co-treatment with 
PLX4720 weakened this up-regulation, possibly due to a decreased NFκB activity upon 
RAF inhibitor treatment (Fig. 3a). The mRNA levels of c-IAP2 were regulated in a similar 
pattern (Fig. 3b). Regulation of c-FLIP was more complex. TNFα alone induced c-FLIP 
protein expression in M238 cells, while PLX4720 treatment alone slightly enhanced c-FLIP 
expression in A375 cells (Fig. 3a and Fig. S5). Multiple forms of c-FLIP provide protection 
from death-receptor-mediated apoptosis (Golks et al., 2005; Krueger et al., 2001; Scaffidi et 
al., 1999) and we detected up-regulation of the long isoform, c-FLIP_L, in our studies. The 
mRNA levels of c-FLIP were up-regulated by TNFα alone or TNFα with PLX4720 in A375 
and M238 cells (Fig. 3b). Despite this complexity, a consistent observation was that c-FLIP 
expression was up-regulated in the combined TNFα and PLX4720 treated cells versus 
PLX4720 alone treated cells (Fig. 3a, and quantitated in Fig. S5). This observation was also 
confirmed in M229 cells (Fig. S4b-c).
To confirm that the regulation of c-IAP2 and c-FLIP by TNFα are dependent on NFκB, we 
analyzed their expression in A375 and M238 cells depleted of NFκB subunits (Fig. 3c). 
Consistent with data above, in control siRNA-treated A375 and M238 cells, PLX4720 and 
TNFα combination treatment enhanced the expression of c-IAP2 and c-FLIP when 
compared to PLX4720 alone treatment. However, the up-regulation of both proteins was 
blunted in p50 or p65-depleted cells indicating that the regulation of c-IAP2 and c-FLIP is 
NFκB-dependent.
c-FLIP but not c-IAP2 is required for TNFα-induced protection against PLX4720
Since both c-IAP2 and c-FLIP play anti-apoptotic roles (Liston et al., 1996; Safa and Pollok, 
2011), we tested individually the requirement for these two proteins in TNFα-induced 
protection against PLX4720. Selective siRNAs effectively reduced the induction of c-IAP2 
(>90% and 75% down-regulation in M238 and M229, respectively) and c-FLIP (>90% and 
87% down-regulation in M238 and M229, respectively) by TNFα and PLX4720 (Fig. 4a). 
Surprisingly, cells depleted of c-IAP2 were still protected by TNFα against PLX4720-
induced apoptosis to a level comparable to control transfected cells (Fig. 4b). By contrast, 
depletion of c-FLIP completely restored cell death in the presence of TNFα and PLX4720 
(Fig. 4b and Fig. S6). Similarly, the cleavage of caspase 3, 8 and 9 in the TNFα plus 
PLX4720 treatment samples was recovered, at least partially, to the level of PLX4720 
treatment alone samples in c-FLIP-depleted but not c-IAP2-depleted M238 and M229 cells 
(Fig. 4a). c-FLIP depletion had no impact on cell death induced by ERK1/2 pathway-
independent drugs such as etoposide and cisplatin (Fig. S3). These results suggest that c-
FLIP but not c-IAP2 is required for TNFα-mediated protection against RAF inhibitor.
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Over-expression of c-FLIP protects melanoma cells against PLX4720-induced apoptosis
To further test the role of c-FLIP as the pro-survival effector downstream of NFκB, we 
examined whether c-FLIP was sufficient to protect against PLX4720-induced apoptosis. We 
stably expressed either c-FLIP_S (short isoform), c-FLIP_L (long isoform) or LacZ (as a 
control) in A375 cells, as verified by Western blotting (Fig. 5a). We then tested for the 
response to PLX4720. PLX4720 treatment led to decreased expression of transgenes, 
presumably due to reduced CMV promoter activity upon ERK1/2 signaling inhibition (Chen 
and Stinski, 2002). Consistent with prior results, treatment of RAF inhibitor induced 
approximately 45% cell death in LacZ-expressing A375 cells (Fig. 5b). Ectopic expression 
of c-FLIP_S or c-FLIP_L decreased cell death to 12% or 16%, respectively. The reduction 
in cell death was associated with lower detectable levels of cleaved caspase 3, 8 and 9 (Fig. 
5a). To confirm that the protective role of c-FLIP was not cell line dependent, we conducted 
similar experiments in M229 cells and used another negative control, GFP (Fig. 5c-d). GFP-
expressing M229 cells exhibited 48% cell death after RAF inhibitor treatment, which was 
decreased to 34% or 28% following c-FLIP_S or c-FLIP_L expression, respectively. 
Therefore, c-FLIP isoforms are sufficient to protect mutant BRAF melanoma cells from 
PLX4720-induced cell death.
Targeting p65-NFκB enhances the response to PLX4720 in vitro and in vivo
Prompted by our observations, we hypothesized that targeting the NFκB pathway may 
synergize with the RAF inhibitor, PLX4720. p65 is a major component of the NFκB 
signaling complex; thus, we generated two 1205Lu cell lines (1205TR p65 shRNA #2 and 
#3) harboring a doxycycline-inducible shRNA targeting p65. In the absence of doxycycline, 
PLX4720 treatment induced 5-10% cell death after 24 hours and 40-50% after 48 hours in 
both cell lines in vitro (Fig. 6b). Treatment of doxycycline led to efficient knockdown of p65 
and reduction in c-FLIP expression in both cell lines and significantly increased cell death 
after 24 and 48 hours of PLX4720 treatment (Fig. 6a-b).
We further tested this hypothesis in a mouse xenograft model using A375 cells expressing 
either control non-targeting or p65-specific shRNAs controlled by doxycycline. A375TR 
cells were used for their reproducible tumor forming ability in nude mice and efficient 
doxycycline inducible knockdowns (Abel et al., 2013). Doxycycline treatment significantly 
decreased p65 expression in A375TR p65 shRNA #2 and #3 cells (Fig. 6c). In vivo, p65 
shRNA induction had marginal impact on tumor growth in the absence of the RAF inhibitor. 
Treatment with the RAF inhibitor alone partially inhibited tumor growth, consistent with 
partial resistance of this cell line to RAF inhibitor-induced cell death (Shao and Aplin, 
2010). Remarkably, tumor growth was further inhibited when RAF inhibitor was combined 
with p65 depletion (Fig. 6d). Analysis of harvested tumors at the end of the xenograft 
experiment showed reduction of p65 with shRNAs (Fig. S7) although levels were variable 
due to the late time point of harvesting (day 28) and the presence of stromal cells. In 
summary, targeting the NFκB pathway enhances the response to RAF inhibitor in vivo.
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DISCUSSION
The response in mutant BRAF melanoma patients to the RAF inhibitors is heterogeneous 
(Hartsough et al., 2014). While many forms of acquired resistance involve changes in the 
allelic frequency of mutations that re-activate the RAF-MEK-ERK1/2 pathway, factors in 
the tumor microenvironment are important in modulating the primary response to RAF 
inhibitors (Abel et al., 2013; Straussman et al., 2012; Wilson et al., 2012). In this study, we 
showed that TNFα modulates the apoptotic response of mutant BRAF melanoma cells to the 
RAF inhibitor, PLX4720, in an NFκB-dependent manner. This work builds on previous 
studies showing that TNFα blocks apoptosis in melanoma cells treated with MEK inhibitors/
depleted for BRAF (Gray-Schopfer et al., 2007) and adds TNFα to the list of factors that 
provide protection against RAF inhibitor monotherapy and the RAF/MEK inhibitor 
combination.
Our results showed that TNFα protects melanoma cells against the RAF inhibitor-induced 
apoptosis by up-regulation of c-FLIP. Furthermore, ectopic expression of c-FLIP is 
sufficient to decrease RAF inhibitor-induced apoptosis in the absence of exogenous TNFα. 
The molecular details of c-FLIP-mediated protection remain unclear. c-FLIP is generally 
implicated in protection against extrinsic apoptosis although the long isoform, c-FLIP_L, 
may either promote or inhibit apoptosis depending on its expression level (Chang et al., 
2002). In the extrinsic apoptosis pathway, activated death receptors induce the assembly of 
death-inducing signaling complex (DISC). DISC recruits the Fas-associated death domain-
containing protein (FADD), which in turn recruits pro-caspase 8 via its death-effector 
domain (DED) for self-cleavage and activation. All three c-FLIP isoforms (c-FLIP_L, c-
FLIP_S and c-FLIP_R) carry two DEDs at the N terminus, which enable them to compete 
with pro-caspase 8 for binding to FADD and prevent apoptosis (Irmler et al., 1997; Rasper 
et al., 1998). c-FLIP may contribute to RAF inhibitor resistance by preventing caspase 8 
activation induced by RAF inhibitor. Indeed, over-expression of c-FLIP rescued PLX4720-
induced apoptosis with a concurrent reduction in caspase 8 cleavage, as well as cleavage of 
caspase 3 and 9 (Fig. 5a); knockdown of c-FLIP led to the recovery of caspase 8 cleavage 
that was inhibited by TNFα plus PLX4720 treatment (Fig. 4a). In addition, caspase 8 
interference protected melanoma cells against PLX4720 but not etoposide treatment (Fig. 
S8). While our data implicate the c-FLIP-caspase 8 axis in the protective role of TNFα 
against the RAF inhibitor, it is still possible that c-FLIP protects melanoma cells against 
PLX4720 through other downstream targets. For example, c-FLIP may counteract the 
activation of caspase 10, another caspase activated upon DISC engagement (Safa and 
Pollok, 2011). Previous studies have shown that c-FLIP expression is elevated in melanoma 
compared to benign melanocytic lesions (Bullani et al., 2001) and suppression of c-FLIP 
expression sensitizes melanoma cells to death ligand-induced apoptosis (Geserick et al., 
2008). Thus, strategies to decrease c-FLIP expression may prove efficacious for melanoma.
Consistent with previous studies (Kreuz et al., 2001), we found in melanoma cells that 
TNFα up-regulated c-FLIP at the transcriptional level in an NFκB-dependent manner. The 
regulation of c-FLIP may be complex since it is regulated by several transcription factors 
(Safa et al., 2008) and post-translational regulation may also occur (Chang et al., 2006). 
Nevertheless, c-FLIP protein level was consistently elevated in PLX4720 and TNFα co-
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treated cells compared to cells treated with PLX4720 alone, supporting its protective role 
against PLX4720.
Studies on resistance to RAF inhibitors have mainly focused on the RAF-MEK-ERK and 
PI3K-AKT pathways. We present a mechanism of resistance and possible therapeutic 
strategies. Importantly, we identified NFκB pathway as an anti-apoptotic signal in RAF 
inhibitor-treated melanoma cells and co-targeting mutant BRAF and the NFκB pathway had 
enhanced anti-tumor effects in vitro and in vivo compared to targeting either pathway alone. 
The NFκB pathway is implicated in chemo-/radio-therapy resistance of many cancers and is 
readily targetable. Various compounds target this pathway at different levels. Bortezomib, a 
proteasome inhibitor, inhibits NFκB pathway by preventing the degradation of the NFκB 
inhibitor, IκB. The small molecule, BMS-345541, specifically inhibits the NFκB upstream 
activating kinase, IKKβ (Burke et al., 2003). Furthermore, NEMO-binding-domain peptides 
block the interaction between NEMO and IκB kinase complex (May et al., 2000). Tumor-
associated macrophages (TAM) are a major source of TNFα in tumor microenvironment 
and TAM infiltration into tumors is enhanced by RAF and MEK inhibitor treatment (Smith 
et al., 2014). Targeting TAMs may be a viable alternative to direct NFκB intervention and 
the clinical efficacy of combined treatment of macrophage inhibitor, PLX3397, and 
vemurafenib on BRAF V600E melanoma patients is under investigation.
In summary, our findings underline the importance of the tumor microenvironment 
component, TNFα, to the responsiveness of BRAF V600E melanoma cells to RAF 
inhibitors and provide a strong rationale for the strategy of co-targeting the RAF-MEK-
ERK1/2 pathway and the TNFα/NFκB axis to treat this subset of melanomas.
MATERIALS AND METHODS
Reagents
PLX4720 was provided by Dr. Gideon Bollag and Plexxikon Inc. (Berkeley, CA, USA). 
TNFα was purchased from Sigma-Aldrich (St. Louis, MO, USA). Doxycycline was 
obtained from Thermo Scientific (Rockford, IL, USA).
Cell Culture
Melanoma cells were cultured as previously described (Abel et al., 2013; Shao and Aplin, 
2012). Cell lines were sequenced at multiple loci. 1205LuTR and A375TR are sublines with 
high Tet repressor expression (Abel et al., 2013).
Western Blotting
Western blotting was performed, as previously described (Shao and Aplin, 2010). 
Antibodies against Bcl-xL, phospho-ERK1/2 (Thr202/Tyr204), caspase 8, caspase 9, 
caspase 3, c-IAP1, cIAP2, XIAP, livin, survivin, p50 and HA-tag were purchased from Cell 
Signaling Technology (Beverley, MA, USA). ERK2, p65 antibodies were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Additionally antibodies towards 
Bcl-2 and Mcl-1 (BD Biosciences, San Jose, CA, USA), anti-actin (Sigma-Aldrich), Bim 
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(Stressgen, San Diego, CA, USA), Bmf (ENZO Life Science, Farmingdale, NY, USA), and 
c-FLIP (Adipogen, San Diego, CA, USA) were utilized.
Luciferase Assay
Melanoma cells were transfected with pNFκB-luc plasmid (2 µg/33 mm well) using Fugene 
HD reagent (Promega, Madison, WI, USA). After 24 hours, cells were harvested and sub-
cultured equally into 8 wells. Next day, 4 wells were treated with −/+ TNFα and −/+ 
PLX4720, respectively, for another 24 hours and lysed for luciferase assay using Dual- 
Luciferase® Reporter Assay Kit (Promega). The other 4 wells were treated in the same 
manner and lysed for Bradford Assay. The luciferase readings were normalized against 
Bradford Assay readings accordingly and plotted against each treatment condition.
Quantitative RT-PCR
Total RNA isolation and qRT-PCR were performed as previously described (Shao and 
Aplin, 2010). Primer sequences are provided in the Supplemental Information.
Propidium Iodide (PI) Staining
Cells were treated with indicated drugs for 24 hours and then washed in PBS and fixed in 
70% ethanol for 2 hours. Fixed cells were washed in PBS, pelleted and resuspended in 500 
µl PI staining buffer (PBS with 40 µg/ml PI (Sigma-Aldrich), 100 µg/ml RNaseA (Thermo 
Scientific) and 0.1% Triton-X 100. Cells were stained for 30 minutes at room temperature 
and analyzed by flow cytometry on a FACS Calibur. Data were analyzed using Flowjo 
software (Three Star, Inc., Ashland, OR, USA).
RNA Interference
Cells were transfected for 72 hours with 12.5 nM small-interfering RNAs (siRNA) and 
Lipofectamine RNAiMAX (Invitrogen). siRNAs for p50 
(GCAAUAGCCUGCCAUGUUU), p65 (GGAUUGAGGAGAAACGUAA), c-IAP2 
(UCAAUGAUCUUGUGUUAGA), c-FLIP (GAUGUGUCCUCAUUAAUUU), and non-
targeting siRNA control (UAGCGACUAAACACAUCAA) were purchased from 
Dharmacon (Lafayette, CO, USA).
Lentiviral cDNA Constructs
c-FLIP cDNA isoforms (HA-c-FLIP-L and HA-c-FLIP-S) were amplified from a melanoma 
cDNA pool to incorporate a HA-tag using KOD hot Start DNA polymerase kit. DNA 
fragments were cloned into pENTR™/D-TOPO vector (Invitrogen) and the resultant entry 
plasmids were then recombined with pLentipuro/TO/V5-DEST. Lentivirus were produced in 
293FT cells (Shao and Aplin, 2010) and melanoma cells were infected with lentivirus for 72 
hours before selection with puromycin.
Lentiviral shRNA Constructs
DNA oligonucleotides were annealed and ligated into pENTR/H1/TO using the 
manufacturer’s kit and instructions (Invitrogen). The sequences are provided in the 
Supplemental Information. shRNA cassettes were recombined into a destination vector with 
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puromycin resistance. Lentiviruses were produced and melanoma cells were transduced, as 
above.
Animal Studies
A375TR cells (1 × 106/mouse) were intradermally injected into female athymic mice (NU/J: 
Jackson) and allowed to grow for 7 days to reach palpable tumor size (40-100 mm3). Mice 
were then exposed to drinking water containing doxycycline (2 mg/ml) and three days later 
fed with control chow or PLX4720 chow (90 mg/kg PLX4720). The first measure of tumor 
size was taken (day 0). Subsequently, measurements were taken twice a week using digital 
calipers, and tumor volume was determined by the following formula: volume = (length × 
width2) × 0.52. Mice were euthanized when tumor volume reached 1000 mm3.
Statistical Analysis
For in vitro experiments, statistical significance of differences between the results was 
evaluated using a student two-tailed t test assuming non-equal variance. For in vivo data, 
statistical analysis was conducted using a mixed-effects model and Tukey’s corrected 
pairwise comparisons of mean fold change in volume between treatment groups (SAS 
statistical software).
Animal Study approval
All animal experiments were approved by the Institutional Animal Care and Use Committee 
and conducted in an Association for the Assessment and Accreditation of Laboratory 
Animal Care accredited facility at Thomas Jefferson University.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
We are grateful to Drs. Antoni Ribas (UCLA) and Meenhard Herlyn (Wistar Institute, Philadelphia) for the 
provision of cells and Dr. Gideon Bollag and Plexxikon Inc. (Berkeley, CA, USA) for RAF inhibitor. We thank Dr. 
Tingting Zhan for help with statistics. This study was supported by NIH grants R01-GM067893 (AE Aplin), an 
Outrun the Sun fellowship (Y Shao), a grant from the Pennsylvania Department of Health (AE Aplin) and a 
Fundamental Research Funds for the Central Universities of China (Y Shao). The Department specifically 
disclaims responsibility for any analysis, interpretation or conclusion. The Sidney Kimmel Cancer Center is 
supported by National Cancer Institute Support Grant 1P30CA56036.
Abbreviations
NFκB nuclear factor κB
c-FLIP cellular caspase 8 (FLICE)-like inhibitory protein
ERK1/2 extracellular signal-regulated kinase 1/2
RTK receptor tyrosine kinase
TAM tumor-associated macrophages
Shao et al. Page 9
J Invest Dermatol. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
siRNA small interfering RNA
shRNA short hairpin RNA
REFERENCES
Abel EV, Basile KJ, Kugel CH III, et al. Melanoma adapts to RAF/MEK inhibitors by FOXD3-
dependent upregulation of ERBB3 by FOXD3. J Clin Invest. 2013; 123:2155–68. [PubMed: 
23543055] 
Amiri KI, Horton LW, LaFleur BJ, et al. Augmenting chemosensitivity of malignant melanoma tumors 
via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent 
for malignant melanoma. Cancer Res. 2004; 64:4912–8. [PubMed: 15256463] 
Boisvert-Adamo K, Longmate W, Abel EV, et al. Mcl-1 is required for melanoma resistance to 
anoikis. Mol Cancer Res. 2009; 7:549–56. [PubMed: 19372583] 
Bullani RR, Huard B, Viard-Leveugle I, et al. Selective expression of FLIP in malignant melanocytic 
skin lesions. J Invest Dermatol. 2001; 117:360–4. [PubMed: 11511316] 
Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B 
kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription 
in mice. J Biol Chem. 2003; 278:1450–6. [PubMed: 12403772] 
Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance 
in prostate cancer. Oncogene. 2001; 20:7342–51. [PubMed: 11704864] 
Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and 
CD95-mediated apoptosis. Embo J. 2002; 21:3704–14. [PubMed: 12110583] 
Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to 
TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006; 124:601–13. [PubMed: 
16469705] 
Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the 
apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000; 20:2687–95. [PubMed: 10733571] 
Chen J, Stinski MF. Role of regulatory elements and the MAPK/ERK or p38 MAPK pathways for 
activation of human cytomegalovirus gene expression. J Virol. 2002; 76:4873–85. [PubMed: 
11967304] 
Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with 
BRAF V600 mutations. N Engl J Med. 2012; 367:1694–703. [PubMed: 23020132] 
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic 
melanoma. N Eng J Med. 2010; 363:809–19.
Geserick P, Drewniok C, Hupe M, et al. Suppression of cFLIP is sufficient to sensitize human 
melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene. 2008; 27:3211–20. 
[PubMed: 18084329] 
Golks A, Brenner D, Fritsch C, et al. c-FLIPR, a new regulator of death receptor-induced apoptosis. J 
Biol Chem. 2005; 280:14507–13. [PubMed: 15701649] 
Gray-Schopfer VC, Karasarides M, Hayward R, et al. Tumor necrosis factor-alpha blocks apoptosis in 
melanoma cells when BRAF signaling is inhibited. Cancer Res. 2007; 67:122–9. [PubMed: 
17210691] 
Hartsough E, Shao Y, Aplin AE. Resistance to RAF inhibitors revisited. J Invest Dermatol. 2014; 
134:319–25. [PubMed: 24108405] 
Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a 
multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380:358–65. [PubMed: 
22735384] 
Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 
1997; 388:190–5. [PubMed: 9217161] 
Shao et al. Page 10
J Invest Dermatol. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Jensen TO, Schmidt H, Moller HJ, et al. Macrophage markers in serum and tumor have prognostic 
impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009; 
27:3330–7. [PubMed: 19528371] 
Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002; 3:221–7. 
[PubMed: 11875461] 
Kawakami H, Tomita M, Matsuda T, et al. Transcriptional activation of survivin through the NF-
kappaB pathway by human T-cell leukemia virus type I tax. International journal of cancer. 2005; 
115:967–74.
Kreuz S, Siegmund D, Scheurich P, et al. NF-kappaB inducers upregulate cFLIP, a cycloheximide-
sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001; 21:3964–73. [PubMed: 
11359904] 
Krueger A, Schmitz I, Baumann S, et al. Cellular FLICE-inhibitory protein splice variants inhibit 
different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol 
Chem. 2001; 276:20633–40. [PubMed: 11279218] 
Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 
2009; 1:a001651. [PubMed: 20457564] 
Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related 
family of IAP genes. Nature. 1996; 379:349–53. [PubMed: 8552191] 
Lito P, Pratilas CA, Joseph EW, et al. Relief of profound feedback inhibition of mitogenic signaling by 
RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012; 22:668–
82. [PubMed: 23153539] 
Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-
mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. 
Lancet Oncol. 2012; 13:1087–95. [PubMed: 23051966] 
Magne N, Toillon RA, Bottero V, et al. NF-kappaB modulation and ionizing radiation: mechanisms 
and future directions for cancer treatment. Cancer Lett. 2006; 231:158–68. [PubMed: 16399220] 
May MJ, D'Acquisto F, Madge LA, et al. Selective inhibition of NF-kappaB activation by a peptide 
that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 2000; 289:1550–
4. [PubMed: 10968790] 
Meng Y, Beckett MA, Liang H, et al. Blockade of tumor necrosis factor alpha signaling in tumor-
associated macrophages as a radiosensitizing strategy. Cancer Research. 2010; 70:1534–43. 
[PubMed: 20145121] 
Meyskens FL Jr. Buckmeier JA, McNulty SE, et al. Activation of nuclear factor-kappa B in human 
metastatic melanomacells and the effect of oxidative stress. Clin Cancer Res. 1999; 5:1197–202. 
[PubMed: 10353757] 
Rasper DM, Vaillancourt JP, Hadano S, et al. Cell death attenuation by 'Usurpin', a mammalian DED-
caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, 
APO-1) receptor complex. Cell Death Differ. 1998; 5:271–88. [PubMed: 10200473] 
Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer 
therapy. Curr Cancer Drug Targets. 2008; 8:37–46. [PubMed: 18288942] 
Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel). 
2011; 3:1639–71. [PubMed: 22348197] 
Scaffidi C, Schmitz I, Krammer PH, et al. The role of c-FLIP in modulation of CD95-induced 
apoptosis. J Biol Chem. 1999; 274:1541–8. [PubMed: 9880531] 
Shao Y, Aplin A. Akt3-mediated resistance to apoptosis in B-RAF targeted melanoma cells. Cancer 
Res. 2010; 70:6670–81. [PubMed: 20647317] 
Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in 
human melanoma. Cell Death Differ. 2012; 19:2029–39. [PubMed: 22858545] 
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated 
with vemurafenib. N Eng J Med. 2012; 366:707–14.
Stehlik C, de Martin R, Binder BR, et al. Cytokine induced expression of porcine inhibitor of apoptosis 
protein (iap) family member is regulated by NF-kappa B. Biochem Biophys Res Commun. 1998a; 
243:827–32. [PubMed: 9501011] 
Shao et al. Page 11
J Invest Dermatol. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Stehlik C, de Martin R, Kumabashiri I, et al. Nuclear factor (NF)-kappaB-regulated X-chromosome-
linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced 
apoptosis. J Exp Med. 1998b; 188:211–6. [PubMed: 9653098] 
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF 
inhibitors through HGF secretion. Nature. 2012; 487:500–4. [PubMed: 22763439] 
Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with 
potent antimelanoma activity. Proc Natl Acad Sci USA. 2008; 105:3041–6. [PubMed: 18287029] 
Smith MP, Sanchez-Laorden B, O'Brien K, et al. The immune microenvironment confers resistance to 
MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Dis. 2014; 4:1214–9.
Torisu H, Ono M, Kiryu H, et al. Macrophage infiltration correlates with tumor stage and angiogenesis 
in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer. 
2000; 85:182–8. [PubMed: 10629075] 
Wang Z, Boudjelal M, Kang S, et al. Ultraviolet irradiation of human skin causes functional vitamin A 
deficiency, preventable by all-trans retinoic acid pre-treatment. Nat Med. 1999; 5:418–22. 
[PubMed: 10202931] 
Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to 
anticancer kinase inhibitors. Nature. 2012; 487:505–9. [PubMed: 22763448] 
Yang J, Richmond A. Constitutive kappa B kinase activity correlates with nuclear factor-kappa B 
Activation in human melanoma cells. Cancer Res. 2001; 61:4901–9. [PubMed: 11406569] 
Shao et al. Page 12
J Invest Dermatol. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. TNFα protects melanoma cells from RAF inhibitor-induced apoptosis
a) Luciferase assays were performed as described in Material and Methods. Cells were 
treated with −/+ 50 ng/ml TNFα and −/+ 5 µM PLX4720 for 24 hours. Average relative 
luciferase activities from three experiments are shown. Error bars represent standard 
deviation. ** p<0.01. b) Cells were treated with −/+ 50 ng/ml TNFα and either −/+ 10 µM 
PLX4720 for 72 hours (A375) or −/+ 5 µM PLX4720 for 48 hours (M238, M229). Cells 
stained with PI for cell cycle analysis. Average percentages of sub-G1 populations from 
three experiments were quantified. * p<0.05; ** p<0.01; *** p<0.001. c) A375, M238 and 
M229 cells were treated with −/+ 50 ng/ml TNFα, −/+ 5 µM PLX4720 for 8-72 hours. Cells 
lysates were analyzed by Western blotting. Arrows indicate full length or cleaved products 
of caspases. Relative levels of cleaved caspases are indicated below the corresponding blots.
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Figure 2. TNFα-induced protection from RAF inhibitors is mediated by NFκB
a) Melanoma cells were transfected with control (Ctrl), p50 or p65 siRNAs for 72 hours. 
Cells lysates analyzed by Western blotting. Knockdown efficiency was estimated by band 
intensity quantitation and shown below the blots. b-d) Melanoma cells were transfected with 
indicated siRNAs for 72 hours and treated with −/+ 50 ng/ml TNFα and −/+ 5 µM PLX4720 
for 48 (M229 and M238) or 72 (A375) hours before harvested for PI cell cycle analysis. 
Average percentage of sub-G1 population from three experiments was plotted for each 
condition. Error bars represent standard deviation. For statistics, one-way ANOVA analyses 
followed by Bonferroni test were performed on TNFα + PLX4720 treatment groups. * 
p<0.05; ** p<0.01; *** p<0.001.
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Figure 3. c-IAP2 and c-FLIP are up-regulated by TNFα and PLX4720 co-treatment
a) A375 and M238 cells were treated with −/+ 50 ng/ml TNFα and −/+ 5 µM PLX4720 for 6 
or 24 hours before analysis by Western blotting. Normalized c-FLIP/Actin band intensity 
ratios were shown. b) A375 and M238 cells were treated as in a) and total RNA isolated and 
qRT-PCR performed on c-IAP2 and c-FLIP genes. Housekeeping genes, actin or EEFA1, 
were internal controls. Average results from three independent experiments are shown. Error 
bars represent standard deviation. * p<0.05; ** p<0.01; *** p<0.001. c) A375 and M238 
cells were transfected with indicated siRNAs for 72 hours and then treated with −/+ 50 
ng/ml TNFα and −/+ 5 µM PLX4720 for additional 24 hours. Cells were lysed for Western 
blotting analysis on indicated proteins. Normalized c-FLIP/Actin band intensity ratios are 
indicated.
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Figure 4. c-FLIP but not cIAP2 is required for TNFα-induced protection against PLX4720
a) M238 or M229 cells were transfected with control, c-IAP2 or c-FLIP specific siRNAs for 
72 hours. Cells were then treated with −/+ 50 ng/ml TNFα and −/+ 5 µM PLX4720 for 
additional 24 hours before lysis for Western blot analysis on indicated proteins. Arrows 
indicate the cleaved forms of the respective caspases. c-IAP2 and c-FLIP knockdown 
efficiency was determined by quantitating the band intensity and the relative levels 
indicated. b) M238 and M229 cells were treated with −/+ 50 ng/ml TNFα and −/+ 5 µM 
PLX4720 for an additional 48 hours after siRNA transfection as in a). Cells were then 
harvested for PI cell cycle analysis. Average percentages of sub-G1 cells from three 
independent experiments were shown for each knockdown condition. Error bars represent 
standard deviation. ** p<0.01.
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Figure 5. c-FLIP over-expression rescues melanoma cells from PLX4720-induced apoptosis
a) A375 cells expressing the indicated transgenes were treated with −/+ 10 µM PLX4720 for 
72 hours. Cells were harvested for Western blotting. b) A375 cells were treated as in a) and 
harvested for PI cell cycle analysis. The average percentage of sub-G1 cells from three 
independent experiments is shown. Error bars represent standard deviation. * p<0.05; ** 
p<0.01. c) M229 cells expressing the indicated transgenes were treated with −/+ 5 µM 
PLX4720 for 48 hours. Cells were harvested for Western blotting. d) M229 cells were 
treated as in c) and harvested for PI cell cycle analysis. Average percentage of sub-G1 cells 
from three independent experiments is shown. Error bars represent standard deviation. * 
p<0.05; ** p<0.01.
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Figure 6. NFκB targeting enhances responses to PLX4720 in vitro and in vivo
a) 1205LuTR p65 shRNA #2 or #3 cells were grown −/+ 100 ng/ml doxycycline for 3 days 
and then lysed for Western blotting on p65, c-FLIP and actin. Quantitation of the c-FLIP 
levels is shown. b) As in a) except cells were treated after 3 days with 5 µM PLX4720 for a 
further 0, 24 or 48 hours and stained with PI. Error bar represents standard deviation. ** 
p<0.01. c) A375TR Ctrl shRNA or A375TR p65 shRNA #2 or #3 cells were cultured −/+ 
100 ng/ml doxycycline for 72 hours and lysed for Western blotting. d) Growth curves of 
tumors formed by A375TR cells harboring control or p65 shRNAs in nude mice fed with 
either PLX4720 or vehicle-laced chow and doxycycline-containing water (n=6 per 
condition). Statistical analysis was performed on relative tumor size differences between 
PLX4720-treated control shRNA group and PLX4720-treated p65 shRNA#2 or #3 group. 
Error bars represent standard errors. * p<0.05, *** p<0.001.
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